期刊文献+

转化生长因子β在器官移植排斥反应中的研究进展 被引量:1

Research Progress of TGF-β in Organ Transplant Rejection
下载PDF
导出
摘要 转化生长因子β(TGF-β)家族是一个有着多效性的细胞因子,具有调节细胞的增殖、分化、迁移、生存等功能。近年来具有免疫抑制功能的TGF-β被广泛承认和研究,在抑制心脏、肾脏、肝脏等器官移植排斥反应方面有较多报道。该文对TGF-β在心脏、肾脏、肝脏等器官移植中的免疫抑制机制进行综述,认为TGF-β是一种诱导和调节移植耐受的细胞因子并介导抗炎作用在免疫反应中起到重要作用。 Transforming growth factor beta (TGF-β) family is a pleiotropie cytokine, regulating cell proliferation,differentiation, survival, migration, and other functions. With immune suppression function ofI TGF-β in recent years being widely recognized and, has been repotted more in the inhibition of the heart, I kidneys, liver and other organ transplant rejection reactions. Here is to make a review of the immunosuppres- β sire mechanism of TGF-β in the heart, kidneys, liver and other organ transplants, and it's considered that TGF-β is an induction and regulation of transplantation tolerant eytokine which plays an important role in the immune resonse through mediating anti-inflammatory effects.
出处 《医学综述》 2014年第9期1559-1561,共3页 Medical Recapitulate
关键词 转化生长因子Β 器官移植 免疫排斥 Transforming growth faetor-β Organ transplantation Immune rejection
  • 相关文献

参考文献2

二级参考文献36

  • 1Turner DM;Williams DM;Sankaran D.An investigation of polymorphism in the interleukin-10 gene promoter,1997.
  • 2Jemal A,Bray F,Center MM, et al.Global cancer statisticsCA A Cancer Journal for Clinicians,2011.
  • 3Okamoto K,Ishida C,Ikebuchi Y,Mandai M,Mimura K,Murawaki Y,Yuasa I.The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Journal of Internal Medicine . 2010
  • 4Zheng SS,Xu X,Wu J,Chen J,Wang WL,Zhang M,et al.Liver transplantation for hepatocellular carcinoma:Hangzhou experiences. Transplantation . 2008
  • 5Li XD,Wu LM,Xie HY,Xu X,Zhou L,Liang TB,et al.Noassociation exists between E-cadherin gene polymorphismand tumor recurrence in patients with hepatocellularcarcinoma after transplantation. Hepatobiliary and Pancreatic Diseases International HBPD Int . 2007
  • 6Chau GY,Wu CW,Lui WY,Chang TJ,Kao HL,Wu LH, et al.Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Annals of Surgery . 2000
  • 7Hsia CY,Huo TI,Chiang SY,Lu MF,Sun CL,Wu JC,Lee PC,Chi CW,Lui WY,Lee SD.Evaluation of interleukin-6,interleukin-10and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. European Journal of Surgical Oncology . 2007
  • 8Wu LM,,Zhang F,Xie HY,et al.MMP2 promoter polymorphism(C-1306T)and risk of recurrence in patients with hepatocellularcarcinoma after transplantation. Clinical Genetics . 2008
  • 9Kamali-Sarvestani E,Aliparasti MR,Atefi S.Association of interleukin -8 (IL-8 or CXCL8) -251T/A and CXCR2 + 1208C/T gene polymorphisms with breast cancer. Neoplasma . 2007
  • 10Ioana Braicu E,Mustea A,Toliat MR,et al.Polymorphism of IL-1alpha,IL-1 beta and IL-10 in patients with advanced ovariancancer:results of a prospective study with 147 patients. Gynecologic Oncology . 2007

共引文献4

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部